Pelthos Therapeutics Statistics
Want to see PTHS full AI Analyst Report?
Pelthos Therapeutics (PTHS) Stock Statistics & Valuation Metrics
Total Valuation
Pelthos Therapeutics has a market cap or net worth of $34.99M. The enterprise value is $148.57M.
- Market Cap
- $34.99M
- Enterprise Value
- $148.57M
Share Statistics
Pelthos Therapeutics has 3,931,829 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,931,829
- Owned by Insiders
- 86.44%
- Owned by Institutions
- 11.86%
Financial Efficiency
Pelthos Therapeutics’s return on equity (ROE) is -1.11 and return on invested capital (ROIC) is -26.38%.
- Return on Equity (ROE)
- -1.11
- Return on Assets (ROA)
- -0.33
- Return on Invested Capital (ROIC)
- -26.38%
- Return on Capital Employed (ROCE)
- -0.31
- Revenue Per Employee
- 182.55K
- Profits Per Employee
- -470.86K
- Employee Count
- 92
- Asset Turnover
- 0.13
- Inventory Turnover
- 0.40
Valuation Ratios
The current PE Ratio of Pelthos Therapeutics is -0.22. Pelthos Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.22
- PS Ratio
- 0.85
- PB Ratio
- -22.14
- Price to FCF
- -0.87
- Price to Operating Cash Flow
- -0.79
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Pelthos Therapeutics had revenue of 16.80M and earned -43.32M in profits. Earnings per share was -23.04.
- Revenue
- 16.80M
- Gross Profit
- 7.43M
- Operating Income
- -32.43M
- Pretax Income
- -50.71M
- Net Income
- -43.32M
- EBITDA
- -45.41M
- Earnings Per Share (EPS)
- -23.04
Cash Flow
In the last 12 months, operating cash flow was -42.30M and capital expenditures -295,000, giving a free cash flow of -42.60M billion.
- Operating Cash Flow
- -42.30M
- Free Cash Flow
- -42.60M
- Free Cash Flow per Share
- -12.03
Dividends & Yields
Pelthos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -115.99%
- Earnings Yield
- -216.46%
Stock Price Statistics
- Beta
- 1.78
- 52-Week Price Change
- -71.55%
- 50-Day Moving Average
- 19.75
- 200-Day Moving Average
- 23.81
- Relative Strength Index (RSI)
- 29.03
- Average Volume (3m)
- 48.94K
Important Dates
Pelthos Therapeutics upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Pelthos Therapeutics as a current ratio of 2.03, with Debt / Equity ratio of 89.58%
- Current Ratio
- 2.03
- Quick Ratio
- 1.12
- Debt to Market Cap
- 0.55
- Net Debt to EBITDA
- -0.37
- Interest Coverage Ratio
- -10.77
Taxes
In the past 12 months, Pelthos Therapeutics has paid -7.39M in taxes.
- Income Tax
- -7.39M
- Effective Tax Rate
- 0.15
Enterprise Valuation
Pelthos Therapeutics EV to EBITDA ratio is -1.36, with an EV/FCF ratio of -2.00.
- EV to Sales
- 1.97
- EV to EBITDA
- -1.36
- EV to Free Cash Flow
- -2.00
- EV to Operating Cash Flow
- -2.02
Balance Sheet
Pelthos Therapeutics has $24.56M in cash and marketable securities with $73.11M in debt, giving a net cash position of -$48.55M billion.
- Cash & Marketable Securities
- $24.56M
- Total Debt
- $73.11M
- Net Cash
- -$48.55M
- Net Cash Per Share
- -$12.35
- Tangible Book Value Per Share
- -$17.96
Margins
Gross margin is 54.72%, with operating margin of -133.42%, and net profit margin of -165.24%.
- Gross Margin
- 54.72%
- Operating Margin
- -133.42%
- Pretax Margin
- -182.30%
- Net Profit Margin
- -165.24%
- EBITDA Margin
- -144.54%
- EBIT Margin
- -156.65%
Analyst Forecast
The average price target for Pelthos Therapeutics is $49.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $49.50
- Price Target Upside
- 427.16% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 3
- AI Score
- 46
